References
- Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am. J. Hyg. 77, 29–37 (1963).
- Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE Jr, Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J. Infect. Dis. 191(8), 1221–1224 (2005).
- Rosen L, Hovis JF, Mastrota FM, Bell JA, Huebner RJ. Observations on a newly recognized virus (Abney) of the reovirus family. Am. J. Hyg. 71, 258–265 (1960).
- Vorburger SA, Pataer A, Swisher SG, Hunt KK. Genetically targeted cancer therapy: tumor destruction by PKR activation. Am. J. Pharmacogenomics 4(3), 189–198 (2004).
- Meurs E, Chong K, Galabru J et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62(2), 379–390 (1990).
- Yoichi I, Goshi N, Shunsuke Y, Akira K, Madoka F, Mamora T. Reovirus oncolysis in human head and neck squamous cell carcinoma cells. Auris Nasus Larynx 31, 407–412 (2004).
- Morris DG, Forsyth PA, Paterson AH et al. A Phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Invest. New Drugs doi:10.1007/s10637-012-9865-z (2012) (Epub ahead of print).
- Errington F, Steele L, Prestwich R et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol. 180(9), 6018–6026 (2008).
- Vidal L, Pandha HS, Yap TA et al. A Phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin. Cancer Res. 14(21), 7127–7137 (2008).
- Prestwich RJ, Errington F, Ilett EJ et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14(22), 7358–7366 (2008).
- Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond Phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 21(2–3), 91–98 (2010).
- Vidal L, Twigger K, White CL et al. Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies. Proc. Am. Assoc. Cancer Res. 47 Abstract 3998 (2005).
- Pandha HS, Heinemann L, Simpson GR et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin. Cancer Res. 15(19), 6158–6166 (2009).
- Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15(8), 1522–1530 (2007).
- Comins C, Spicer J, Protheroe A et al. REO-10: a Phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin. Cancer Res. 16(22), 5564–5572 (2010).
- Lolkema MP, Arkenau HT, Harrington K et al. A Phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin. Cancer Res. 17(3), 581–588 (2011).
- Karapanagiotou EM, Roulstone V, Twigger K et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin. Cancer Res. 18(7), 2080–2089 (2012).
- Kapadia R, Coffey MC. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. Methods 52(4), 301–306 (2010).